TY - JOUR
T1 - Angiogenesis as a new target for cancer treatment
AU - Ono, Mayumi
AU - Izumi, Hiroto
AU - Yoshida, Shigeo
AU - Goto, Daisuke
AU - Jimi, Sei Ichiro
AU - Kawahara, Naoyuki
AU - Shono, Tadahisa
AU - Ushiro, Shin
AU - Ryuto, Masahiro
AU - Kohno, Kimitoshi
AU - Sato, Yasafumi
AU - Kuwano, Michihiko
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 1996
Y1 - 1996
N2 - Neovascularization is often required for rapid growth of solid tumors and also limits vascular metastasis of tumor cells. Neovascularization-targeting agents are a recent innovation that may be a novel means of anticancer therapy. These antiangiogenic drugs have been developed by targeting cell proliferation of vascular endothelial cells, basement-membrane-degrading enzymes, angiogenic factors/receptors, extracellular matrix, angiogenesis signaling, and cell-cell/cell-matrix interactions. In this report, we describe how tumor angiogenesis occurs and how antiangiogenic agents are developed.
AB - Neovascularization is often required for rapid growth of solid tumors and also limits vascular metastasis of tumor cells. Neovascularization-targeting agents are a recent innovation that may be a novel means of anticancer therapy. These antiangiogenic drugs have been developed by targeting cell proliferation of vascular endothelial cells, basement-membrane-degrading enzymes, angiogenic factors/receptors, extracellular matrix, angiogenesis signaling, and cell-cell/cell-matrix interactions. In this report, we describe how tumor angiogenesis occurs and how antiangiogenic agents are developed.
UR - http://www.scopus.com/inward/record.url?scp=0029811670&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029811670&partnerID=8YFLogxK
U2 - 10.1007/s002800051044
DO - 10.1007/s002800051044
M3 - Article
C2 - 8765423
AN - SCOPUS:0029811670
VL - 38
SP - S78-S82
JO - Cancer Chemotherapy and Pharmacology, Supplement
JF - Cancer Chemotherapy and Pharmacology, Supplement
SN - 0943-9404
ER -